bioAffinity Technologies Shares Rise After CyPath Lung Surveillance Update

bioAffinity Technologies (NASDAQ:BIAF) shares rose 39.4% in premarket trading after the company announced that its CyPath® Lung noninvasive diagnostic test is now positioned for post-curative surveillance of lung cancer recurrence.

The company said the test can be used by physicians to monitor lung cancer survivors for recurrence and alongside routine imaging when new pulmonary nodules are identified.

CyPath® Lung had previously been focused primarily on the early detection of lung cancer in high-risk individuals. The latest announcement adds post-treatment surveillance as another potential application for the test.

CyPath Lung Adds Post-Curative Surveillance Application

Under the announced use, CyPath® Lung can be deployed as part of surveillance following curative treatment and when imaging identifies new pulmonary nodules.

The update expands the potential settings in which the company’s diagnostic test can be used, according to the source material.

Reverse Stock Split Reduced Shares in Circulation

The share-price movement followed a 1-for-15 reverse stock split implemented by bioAffinity Technologies and effective August 24, 2026.

The consolidation reduced the number of shares in circulation. A smaller available float can contribute to larger percentage movements in a stock when trading activity changes.

The source material noted that BIAF had experienced increased price volatility since the reverse stock split took effect.

Broader US Market Shows Limited Movement

The wider US equity market provided a comparatively unchanged backdrop during the session. The S&P 500 was broadly flat, while the Nasdaq moved slightly lower.

According to the source material, comparable companies in the noninvasive diagnostics and lung-health sectors had not announced similar developments during the period.

bioAffinity Technologies shares had been trading near their 52-week low before the premarket increase.

bioAffinity Technologies stock price